Finance

Lists
Why is ZNTL down 3.03%?
Dive Deeper
ZNTL:NASDAQ
Zentalis Pharmaceuticals Inc
$2.56
-3.03%
(-0.080) 1D
Oct 12, 12:04:54 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZNTL...
Open
$2.64
High
$2.64
Low
$2.53
Mkt. cap
242.35M
Avg. vol.
1.21M
Volume
184.36K
52-wk high
$6.95
52-wk low
$1.21
EPS
-$1.96
Beta
1.93
Shares outstanding
94.67M
No. of employees
106
Open
$2.64
High
$2.64
Low
$2.53
Mkt. cap
242.35M
Avg. vol.
1.21M
Volume
184.36K
52-wk high
$6.95
52-wk low
$1.21
EPS
-$1.96
Beta
1.93
Shares outstanding
94.67M
No. of employees
106
News stories
From web sources and news partners
About Zentalis Pharmaceuticals Inc
CEO-
Employees106
Founded2014
Headquarters-
SectorBiotechnology
Websitezentalis.com
Analyst ratings
Based on 8 analysts giving stock ratings to ZNTL in the past 3 months
Strong buy
Buy
6
Hold
2
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for ZNTL in the last 3 months.
Highest
Current $2.56
$11.00 (+329.69%)
Average
$8.14 (+217.97%)
Lowest
$5.00 (+95.31%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Leerink Partners
Buy
Upgraded
$8.00
+212.5%
10/05/2026
Yanan Zhu
Wells Fargo
Hold
Maintained
$5.00
+95.3%
09/29/2026
Matt Phipps
William Blair
Buy
Initiated
-
-
09/15/2026
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
$8.00
+212.5%
08/11/2026
Michael Ulz
Morgan Stanley
Hold
Maintained
$5.00
+95.3%
08/07/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Maintained
$10.00
+290.6%
08/07/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$10.00
+290.6%
08/07/2026
Michael King
Rodman & Renshaw
Buy
Initiated
$11.00
+329.7%
07/23/2026
Jay Olson
Oppenheimer
Buy
Initiated
$9.00
+251.6%
06/15/2026
Unknown Analyst
Wedbush
Hold
Maintained
$4.00
+56.2%
05/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$9.00
+251.6%
05/13/2026
Eva Fortea Verdejo
Wells Fargo
Hold
Reiterated
$5.00
+95.3%
05/13/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
22.95M
30.69M
28.72M
35.16M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.78M
3.77M
9.14M
9.23M
Operating expense
33.73M
34.46M
37.86M
44.39M
Total operating expenses
33.73M
34.46M
37.86M
44.39M
Operating income
-33.73M
-34.46M
-37.86M
-44.39M
Other non operating income
-
-
-
-
EBT including unusual items
-26.69M
-34.77M
-35.23M
-42.15M
EBT excluding unusual items
-26.69M
-34.12M
-35.23M
-42.15M
Income tax expense
-
442.00K
120.00K
138.00K
Effective tax rate
-
-1.27%
-0.34%
-0.33%
Other operating expenses
-
-
-
-
Net income
-26.69M
-35.22M
-35.35M
-42.29M
Net profit margin
-
-
-
-
Earnings per share
-0.37
-0.49
-0.50
-0.59
Interest and investment income
7.04M
338.00K
2.62M
2.24M
Interest expense
-
-
-
-
Net interest expenses
7.04M
338.00K
2.62M
2.24M
Depreciation and amortization charges
-
-
-
-
EBITDA
-33.57M
-34.30M
-37.70M
-44.24M
Gain or loss from assets sale
-103.00K
-26.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps